Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
84.39
+0.53 (0.63%)
At close: Nov 5, 2025, 4:00 PM EST
84.60
+0.21 (0.25%)
After-hours: Nov 5, 2025, 4:29 PM EST
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
$856,467
Profits / Employee
$253,787
Market Cap
210.79B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | 71,000 | 2,000 | 2.90% |
| Dec 31, 2018 | 69,000 | 0 | - |
| Dec 31, 2017 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2016 | 68,000 | 0 | - |
| Dec 31, 2015 | 68,000 | -2,000 | -2.86% |
| Dec 31, 2014 | 70,000 | -6,000 | -7.89% |
| Dec 31, 2013 | 76,000 | -7,000 | -8.43% |
| Dec 31, 2012 | 83,000 | -3,000 | -3.49% |
| Dec 31, 2011 | 86,000 | -8,000 | -8.51% |
| Dec 31, 2010 | 94,000 | -6,000 | -6.00% |
| Dec 31, 2009 | 100,000 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| AbbVie | 55,000 |
MRK News
- 1 day ago - Merck and Blackstone enter research agreement to develop cancer therapy for $700 million - Reuters
- 1 day ago - Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT) - Business Wire
- 1 day ago - Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody - Business Wire
- 2 days ago - Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S. - Business Wire
- 3 days ago - Top 10 High-Yield Dividend Stocks For November 2025 - Seeking Alpha
- 4 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Nov. 2025) - Seeking Alpha
- 6 days ago - Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - My Top 10 High-Yield Picks For November 2025: One Yields 9%+ - Seeking Alpha